Japan Tobacco Inc. · TSE:2914

Japan Tobacco — Q3 2017 Earnings Presentation

12 slides from Japan Tobacco's earnings presentation, Nov 1, 2017

  1. Slide 1: 2017 Third Quarter Results (January 1–September 30, 2017)

    2017 Third Quarter Results (January 1–September 30, 2017) Naohiro Minami CFO and Senior Vice President *Please be reminded that the figures shown on these slides may differ from those shown in the financial statements as they are intended to facilitate the reader’s understanding of individual busine

  2. Slide 2: Annotation

    <Annotation> Adjusted operating profit: Adjusted operating profit = operating profit + amortization cost of acquired intangibles Adjusted OP: arising from business acquisitions + adjusted items (income and costs)* * Adjusted items (income and costs) = impairment losses on goodwill ± restructuring in

  3. Slide 3: Consolidated Financial Results

    Consolidated financial results January – September 2017 5 Consolidated Financial Results Adjusted operating profit at constant FX increased (JPY BN) Jan-Sep Jan-Sep Change 2016 2017 vs. PY At constant FX Adjusted Operating Profit 476.5 489.7 +2.8% Reported Revenue 1,618.5 1,592.9 -1.6% Adjusted Oper

  4. Slide 4: International Tobacco Business: Results by business segment

    Results by business segment January – September 2017 7 International Tobacco Business Earnings growth remains on track for full year target (BNU, US$ MM) Jan-Sep Jan-Sep Change 2016 2017 vs. PY Total Shipment Volume 304.2 298.0 -2.0% GFB Shipment Volume 216.3 216.8 +0.2% At Constant FX Core Revenue

  5. Slide 5: International Tobacco Business: Year-on-year variance by cluster

    International Tobacco Business Year-on-year variance by cluster Change vs. PY Jan-Mar Apr-Jun Jul-Sep Jan-Sep 2017 2017 2017 2017 South & West Europe Total Shipment Volume -6.4% 0.9% 0.1% -1.8% GFB Shipment Volume -5.9% 1.3% 0.8% -1.3% Core Revenue at constant FX -5.9% 0.7% -2.9% -2.7% North & Centr

  6. Slide 6: Profit increased led by cost optimization while continuing to invest for sustainable growth

    International Tobacco Business Profit increased led by cost optimization while continuing to invest for sustainable growth (US$MM, at constant FX) Core Revenue Adjusted OP Jan-Sep Jan-Sep 8,062 2016 2,626 2016 Volume -169 Volume -160 -1.5% Price/Mix +48 +9.2% Price/Mix +40 Others* +363 Jan-Sep 2017

  7. Slide 7: Japanese Domestic Tobacco Business: Cigarette sales volume was weak

    Japanese Domestic Tobacco Business Cigarette sales volume was weak and operating environment continues to be challenging (BNU, JPY BN) Jan-Sep Jan-Sep Change 2016 2017 vs. PY Cigarette industry volume 130.8 115.3 -11.8% Cigarette sales volume 79.7 70.3 -11.8% SoM of JT 61.0% 61.0% +0.0%pt Core Reven

  8. Slide 8: Ploom TECH expansion; Pharmaceutical and Processed Food Businesses

    Ploom TECH Ploom TECH: Expanding sales area in Tokyo Expanding sales area in Tokyo June 29th “Ploom Shops” launched July 10th around 100 tobacco stores in the Tokyo metropolitan area ▽ October 30th further expansion to total around 500 tobacco stores in Tokyo 4 Ploom Shops opened in Tokyo November 1

  9. Slide 9: 2017 Revised Forecast

    2017 Revised Forecast 17 Consolidated Financial Forecast Adjusted operating profit at constant FX to grow despite a challenging competitive environment (JPY BN) Change vs. Previous Revised Change Previous Forecast Forecast vs. PY Forecast At constant FX Adjusted Operating Profit 597.0 592.0 -5.0 +0.

  10. Slide 10: International Tobacco and Japanese Domestic Tobacco Forecasts

    International Tobacco Business No change to 9% profit growth target from updated assumptions (BNU, US$MM) Change vs. Previous Revised Change Previous Forecast Forecast vs. PY Forecast Total Shipment Volume 391.0 398.0 +7.0 -0.2% GFB Shipment Volume 288.0 286.0 -2.0 +0.8% At Constant FX Core Revenue

  11. Slide 11: Pharmaceutical and Processed Food Businesses Forecast

    Pharmaceutical and Processed Food Businesses Pharmaceutical: Strong royalty revenue leading to upward revision Processed food: Aiming to achieve profit growth (JPY BN) Change vs. Previous Revised Change Previous Forecast Forecast vs. PY Forecast Pharmaceutical Business Revenue 102.0 103.0 +1.0 +15.8

  12. Slide 12: Closing Remarks

    Closing 23 Closing Remarks Consistently invest in business toward mid- to long- term profit growth  Aim to achieve 2017 profit growth target at constant FX basis Management principle:4Smodel  Continue to invest in emerging products and expand our geographic reach Shareholders  Annual dividend per

Japan Tobacco — Q3 2017 Earnings Presentation on 6ix